ECTS

Twelve Google and IBM Professional Certificates on Coursera Receive ECTS Credit Recommendations

Retrieved on: 
Friday, January 19, 2024

Coursera is announcing today the Foundation for International Business Administration Accreditation (FIBAA) has certified 12 Professional Certificates from Google and IBM, with European Credit Transfer and Accumulation System (ECTS) credit recommendations available exclusively on Coursera.

Key Points: 
  • Coursera is announcing today the Foundation for International Business Administration Accreditation (FIBAA) has certified 12 Professional Certificates from Google and IBM, with European Credit Transfer and Accumulation System (ECTS) credit recommendations available exclusively on Coursera.
  • Now, ministries, higher education institutions, and students can accept and transfer university credit for eligible industry micro-credentials on Coursera at institutions across 49 member nations in the ECC/Bologna process .
  • This cross-sector initiative represents a major step toward establishing a global ecosystem for credit recognition of online learning and industry micro-credentials.
  • In a competitive labor market, universities and employers are increasingly using online learning to bridge skills gaps for graduates.

Coursera Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, October 26, 2023

Coursera, Inc. (NYSE: COUR) today announced financial results for its third quarter ended September 30, 2023.

Key Points: 
  • Coursera, Inc. (NYSE: COUR) today announced financial results for its third quarter ended September 30, 2023.
  • For more information regarding the non-GAAP financial measures discussed in this press release, please see "Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures" below.
  • We have provided a reconciliation of GAAP to non-GAAP financial measures in the financial statement tables for our historical non-GAAP financial results included in this press release.
  • As previously announced, Coursera will hold a conference call to discuss its third quarter 2023 performance today, October 26, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 26, 2023

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.

Key Points: 
  • BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.
  • Details of the presentation are as follows:
    Title: Role of Plasma Inorganic Pyrophosphate in Calciphylaxis: A Prospective Study
    Calciphylaxis is a rare disorder with a high mortality rate that mostly affects patients with end stage kidney disease (ESKD).
  • The estimated incidence of calciphylaxis is at least 1,800 new patients per year in the United States and there are no approved therapies.
  • Inozyme previously presented data at the European Calcified Tissue Society Congress (ECTS) which showed that morbidity and mortality in patients with calciphylaxis were associated with low levels of PPi.

Embraer and CAE strengthen ties to expand global E-Jet E2 training network

Retrieved on: 
Wednesday, August 30, 2023

Embraer-CAE Training Services (ECTS) will launch a new pilot training program and deploy a state-of-the-art E-Jet E2 full-flight simulator (FFS) at the Singapore-CAE Flight Training Centre where training is scheduled to begin in December 2023.

Key Points: 
  • Embraer-CAE Training Services (ECTS) will launch a new pilot training program and deploy a state-of-the-art E-Jet E2 full-flight simulator (FFS) at the Singapore-CAE Flight Training Centre where training is scheduled to begin in December 2023.
  • E2 pilot and cabin crew training programs will be gradually expanded to strategic locations within CAE's global network to support aircraft deliveries.
  • "We are more than ever committed to providing high-quality training programs available in locations close to our E-Jet E2 operators."
  • The E2 training program will feature CAE 7000XR Series full-flight simulators (FFSs), including the innovative CAE Tropos™ 6000XR visual system, as well as CAE XR Series' flight training devices (FTDs).

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 9, 2023

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.

Key Points: 
  • BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.
  • The Company announced the first self-administration of INZ-701 in the open-label Phase 2 portion of the ongoing clinical trial.
  • General and Administrative (G&A) Expenses – G&A expenses were $6.5 million for the quarter ended March 31, 2023, compared to $5.0 million for the prior-year period.
  • Net Loss – Net loss was $17.4 million, or $0.40 loss per share, for the quarter ended March 31, 2023, compared to $16.9 million, or $0.71 loss per share, for the prior-year period.

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

Retrieved on: 
Friday, April 14, 2023

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company’s senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress (ECTS) in Liverpool, UK.

Key Points: 
  • BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company’s senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress (ECTS) in Liverpool, UK.
  • In February 2023, the Company announced positive preliminary pharmacokinetic (PK), pharmacodynamic (PD), and safety data with encouraging patient reported outcome data from the ongoing trial.
  • Dosing is ongoing in the Phase 2 portion of the trial and the Company is on track to report interim clinical data in the third quarter of 2023.
  • The Company also plans to add an additional cohort to investigate the potential for once-weekly dosing in the ongoing trial.

CAE inaugurates first U.S. West Coast business aviation training centre in Nevada

Retrieved on: 
Tuesday, April 4, 2023

LAS VEGAS, April 4, 2023 /PRNewswire/ - Today, CAE inaugurated its newest business aviation training centre and its first on the U.S. West Coast.

Key Points: 
  • LAS VEGAS, April 4, 2023 /PRNewswire/ - Today, CAE inaugurated its newest business aviation training centre and its first on the U.S. West Coast.
  • CAE Las Vegas began operations in October 2022, adding essential business aviation training capacity in the region to help meet the increased demand for business jet pilots.
  • "Offering a strategic location, an attractive business environment, and a highly specialized workforce, Nevada is the perfect location for CAE's first West Coast business aviation training centre.
  • Business aviation customers at the new training centre have complete access to CAE's industry-leading technology and training expertise to elevate their safety, efficiency, and readiness.

Woolf Launches Airlock - the World's First API for Higher Education Accreditation

Retrieved on: 
Wednesday, November 16, 2022

Airlock allows organizations to connect to Woolf by API to have their learning content benchmarked for accreditation value and matched to an accreditation license.

Key Points: 
  • Airlock allows organizations to connect to Woolf by API to have their learning content benchmarked for accreditation value and matched to an accreditation license.
  • Airlock combines an API with novel technologies for measuring student learning (US patent pending) to create a complete picture of each student's learning experience.
  • Woolf's core accreditation engine matches these experiences with regulated accreditation requirements to determine whether students can be issued with credits.
  • Scaler Neovarsity , a constituent college of Woolf uses Airlock to manage accreditation for graduate degrees in Artificial Intelligence and Machine Learning.

Woolf Launches Airlock - the World's First API for Higher Education Accreditation

Retrieved on: 
Wednesday, November 16, 2022

Airlock allows organizations to connect to Woolf by API to have their learning content benchmarked for accreditation value and matched to an accreditation license.

Key Points: 
  • Airlock allows organizations to connect to Woolf by API to have their learning content benchmarked for accreditation value and matched to an accreditation license.
  • Airlock combines an API with novel technologies for measuring student learning (US patent pending) to create a complete picture of each student's learning experience.
  • Woolf's core accreditation engine matches these experiences with regulated accreditation requirements to determine whether students can be issued with credits.
  • Scaler Neovarsity , a constituent college of Woolf uses Airlock to manage accreditation for graduate degrees in Artificial Intelligence and Machine Learning.

Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 10, 2022

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.

Key Points: 
  • Cash, cash equivalents and investments as of quarter end, together with proceeds from April 2022 offering, extends runway into the fourth quarter of 2023
    BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.
  • Inozyme plans to report topline data from the ongoing trial in the second half of 2022.
  • The Company is on track to report preliminary biomarker and safety data in the second quarter of 2022.
  • Inozyme expects to commence prospective natural history studies of both populations in the second quarter of 2022.